Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells

Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2001-02, Vol.413 (2), p.131-141
Hauptverfasser: Tkaczyk-Gobis, Katarzyna, Tarasiuk, Jolanta, Seksek, Olivier, Stefanska, Barbara, Borowski, Edward, Garnier-Suillerot, Arlette
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 141
container_issue 2
container_start_page 131
container_title European journal of pharmacology
container_volume 413
creator Tkaczyk-Gobis, Katarzyna
Tarasiuk, Jolanta
Seksek, Olivier
Stefanska, Barbara
Borowski, Edward
Garnier-Suillerot, Arlette
description Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity of many natural cytotoxins. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the pump-mediated efflux. Here, we studied three members of a new family of benzoperimidine antitumor compounds which exhibit comparable cytotoxicity towards resistant cells expressing P-glycoprotein, or MRP1, and sensitive cells. We used spectrofluorometric methods to determine the kinetics of the uptake and release of these three drugs in different cell lines: the erythroleukemia cell line K562 and the resistant K562/Adr expressing P-glycoprotein, the small-cell lung cancer cell line GLC4 and resistant GLC4/Adr expressing MRP1. We also studied, using confocal microscopy, the intracellular distribution of these drugs in NIH/3T3 cells. Our data show that (i) the kinetics for the uptake of these drugs is very rapid, higher than 2×10 −17 mole cell −1 s −1, (ii) the drugs are strongly accumulated in the nucleus and lysosomes, (iii) the three drugs are recognized and pumped out by both transporters, as shown by the inhibition of P-glycoprotein- and MRP1-mediated efflux of pirarubicin by benzoperimidine, with inhibitory constants of 1.5 and 2.1 μM for P-glycoprotein and MRP1, respectively, suggesting that benzoperimidine is transported by the two transporters with K m∼2 μM. In conclusion, the fast uptake kinetics of the benzoperimidines counterbalance their efflux by P-glycoprotein and MRP1.
doi_str_mv 10.1016/S0014-2999(01)00728-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70651589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299901007282</els_id><sourcerecordid>70651589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-5bc83332160ff12fb707e7f6cc576281e85719e24bb9beb5088063f801cb0f23</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EotvCTwBZQkLlEBg7dWyfKlTxJVXiwN6t2BmDUWIH2wGVX0-yu2qPHEZzeebjfQh5weAtA9a9-wbArhqutb4E9gZActXwR2THlNQNSMYfk909ckbOS_kJAEJz8ZScMcZ516puR8o-97HMKVeaPI34h8YUG5dTKU3GEkrtY6VrhbpMKVOXpjktcSgbXn8gtRj_phlzmMIQIlLfT2G8oyHSaRlrGPLynT4scjiO5Rl54vux4PNTvyD7jx_2N5-b26-fvty8v21cq3RthHWqbVvOOvCecW8lSJS-c07IjiuGSkimkV9Zqy1aAUpB13oFzFnwvL0gr49r55x-LViqmULZHugjpqUYCZ1gQukVFEfwEDujN_Map893hoHZZJuDbLOZNMDMQbbZDrw8HVjshMPD1MnuCrw6AX1x_ehX1S6Ue06DEIKt1PWRwtXF74DZFBcwOhxCRlfNkMJ_HvkHtxudhg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70651589</pqid></control><display><type>article</type><title>Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tkaczyk-Gobis, Katarzyna ; Tarasiuk, Jolanta ; Seksek, Olivier ; Stefanska, Barbara ; Borowski, Edward ; Garnier-Suillerot, Arlette</creator><creatorcontrib>Tkaczyk-Gobis, Katarzyna ; Tarasiuk, Jolanta ; Seksek, Olivier ; Stefanska, Barbara ; Borowski, Edward ; Garnier-Suillerot, Arlette</creatorcontrib><description>Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity of many natural cytotoxins. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the pump-mediated efflux. Here, we studied three members of a new family of benzoperimidine antitumor compounds which exhibit comparable cytotoxicity towards resistant cells expressing P-glycoprotein, or MRP1, and sensitive cells. We used spectrofluorometric methods to determine the kinetics of the uptake and release of these three drugs in different cell lines: the erythroleukemia cell line K562 and the resistant K562/Adr expressing P-glycoprotein, the small-cell lung cancer cell line GLC4 and resistant GLC4/Adr expressing MRP1. We also studied, using confocal microscopy, the intracellular distribution of these drugs in NIH/3T3 cells. Our data show that (i) the kinetics for the uptake of these drugs is very rapid, higher than 2×10 −17 mole cell −1 s −1, (ii) the drugs are strongly accumulated in the nucleus and lysosomes, (iii) the three drugs are recognized and pumped out by both transporters, as shown by the inhibition of P-glycoprotein- and MRP1-mediated efflux of pirarubicin by benzoperimidine, with inhibitory constants of 1.5 and 2.1 μM for P-glycoprotein and MRP1, respectively, suggesting that benzoperimidine is transported by the two transporters with K m∼2 μM. In conclusion, the fast uptake kinetics of the benzoperimidines counterbalance their efflux by P-glycoprotein and MRP1.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(01)00728-2</identifier><identifier>PMID: 11226386</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>3T3 Cells - drug effects ; 3T3 Cells - metabolism ; Animals ; Antibiotics, Antineoplastic - pharmacology ; Antineoplastic agents ; Antineoplastic Agents - metabolism ; Antineoplastic Agents - pharmacology ; ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects ; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism ; Benzoperimidine ; Biological and medical sciences ; Cell Nucleus - metabolism ; Chemotherapy ; DNA - metabolism ; Doxorubicin - analogs &amp; derivatives ; Doxorubicin - pharmacology ; Drug Resistance, Multiple - physiology ; Drug Screening Assays, Antitumor - methods ; Genes, MDR - drug effects ; Genes, MDR - physiology ; Humans ; K562 Cells - drug effects ; K562 Cells - metabolism ; Lysosomes - metabolism ; Medical sciences ; Mice ; MRP1 (multidrug resistance-associated protein) ; Multidrug resistance ; P-glycoprotein ; Pharmacology. Drug treatments ; Quinazolines - chemistry ; Quinazolines - metabolism</subject><ispartof>European journal of pharmacology, 2001-02, Vol.413 (2), p.131-141</ispartof><rights>2001 Elsevier Science B.V.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-5bc83332160ff12fb707e7f6cc576281e85719e24bb9beb5088063f801cb0f23</citedby><cites>FETCH-LOGICAL-c389t-5bc83332160ff12fb707e7f6cc576281e85719e24bb9beb5088063f801cb0f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014299901007282$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=905551$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11226386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tkaczyk-Gobis, Katarzyna</creatorcontrib><creatorcontrib>Tarasiuk, Jolanta</creatorcontrib><creatorcontrib>Seksek, Olivier</creatorcontrib><creatorcontrib>Stefanska, Barbara</creatorcontrib><creatorcontrib>Borowski, Edward</creatorcontrib><creatorcontrib>Garnier-Suillerot, Arlette</creatorcontrib><title>Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity of many natural cytotoxins. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the pump-mediated efflux. Here, we studied three members of a new family of benzoperimidine antitumor compounds which exhibit comparable cytotoxicity towards resistant cells expressing P-glycoprotein, or MRP1, and sensitive cells. We used spectrofluorometric methods to determine the kinetics of the uptake and release of these three drugs in different cell lines: the erythroleukemia cell line K562 and the resistant K562/Adr expressing P-glycoprotein, the small-cell lung cancer cell line GLC4 and resistant GLC4/Adr expressing MRP1. We also studied, using confocal microscopy, the intracellular distribution of these drugs in NIH/3T3 cells. Our data show that (i) the kinetics for the uptake of these drugs is very rapid, higher than 2×10 −17 mole cell −1 s −1, (ii) the drugs are strongly accumulated in the nucleus and lysosomes, (iii) the three drugs are recognized and pumped out by both transporters, as shown by the inhibition of P-glycoprotein- and MRP1-mediated efflux of pirarubicin by benzoperimidine, with inhibitory constants of 1.5 and 2.1 μM for P-glycoprotein and MRP1, respectively, suggesting that benzoperimidine is transported by the two transporters with K m∼2 μM. In conclusion, the fast uptake kinetics of the benzoperimidines counterbalance their efflux by P-glycoprotein and MRP1.</description><subject>3T3 Cells - drug effects</subject><subject>3T3 Cells - metabolism</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects</subject><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</subject><subject>Benzoperimidine</subject><subject>Biological and medical sciences</subject><subject>Cell Nucleus - metabolism</subject><subject>Chemotherapy</subject><subject>DNA - metabolism</subject><subject>Doxorubicin - analogs &amp; derivatives</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug Resistance, Multiple - physiology</subject><subject>Drug Screening Assays, Antitumor - methods</subject><subject>Genes, MDR - drug effects</subject><subject>Genes, MDR - physiology</subject><subject>Humans</subject><subject>K562 Cells - drug effects</subject><subject>K562 Cells - metabolism</subject><subject>Lysosomes - metabolism</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>MRP1 (multidrug resistance-associated protein)</subject><subject>Multidrug resistance</subject><subject>P-glycoprotein</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinazolines - chemistry</subject><subject>Quinazolines - metabolism</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EotvCTwBZQkLlEBg7dWyfKlTxJVXiwN6t2BmDUWIH2wGVX0-yu2qPHEZzeebjfQh5weAtA9a9-wbArhqutb4E9gZActXwR2THlNQNSMYfk909ckbOS_kJAEJz8ZScMcZ516puR8o-97HMKVeaPI34h8YUG5dTKU3GEkrtY6VrhbpMKVOXpjktcSgbXn8gtRj_phlzmMIQIlLfT2G8oyHSaRlrGPLynT4scjiO5Rl54vux4PNTvyD7jx_2N5-b26-fvty8v21cq3RthHWqbVvOOvCecW8lSJS-c07IjiuGSkimkV9Zqy1aAUpB13oFzFnwvL0gr49r55x-LViqmULZHugjpqUYCZ1gQukVFEfwEDujN_Map893hoHZZJuDbLOZNMDMQbbZDrw8HVjshMPD1MnuCrw6AX1x_ehX1S6Ue06DEIKt1PWRwtXF74DZFBcwOhxCRlfNkMJ_HvkHtxudhg</recordid><startdate>20010216</startdate><enddate>20010216</enddate><creator>Tkaczyk-Gobis, Katarzyna</creator><creator>Tarasiuk, Jolanta</creator><creator>Seksek, Olivier</creator><creator>Stefanska, Barbara</creator><creator>Borowski, Edward</creator><creator>Garnier-Suillerot, Arlette</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010216</creationdate><title>Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells</title><author>Tkaczyk-Gobis, Katarzyna ; Tarasiuk, Jolanta ; Seksek, Olivier ; Stefanska, Barbara ; Borowski, Edward ; Garnier-Suillerot, Arlette</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-5bc83332160ff12fb707e7f6cc576281e85719e24bb9beb5088063f801cb0f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>3T3 Cells - drug effects</topic><topic>3T3 Cells - metabolism</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects</topic><topic>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</topic><topic>Benzoperimidine</topic><topic>Biological and medical sciences</topic><topic>Cell Nucleus - metabolism</topic><topic>Chemotherapy</topic><topic>DNA - metabolism</topic><topic>Doxorubicin - analogs &amp; derivatives</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug Resistance, Multiple - physiology</topic><topic>Drug Screening Assays, Antitumor - methods</topic><topic>Genes, MDR - drug effects</topic><topic>Genes, MDR - physiology</topic><topic>Humans</topic><topic>K562 Cells - drug effects</topic><topic>K562 Cells - metabolism</topic><topic>Lysosomes - metabolism</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>MRP1 (multidrug resistance-associated protein)</topic><topic>Multidrug resistance</topic><topic>P-glycoprotein</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinazolines - chemistry</topic><topic>Quinazolines - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tkaczyk-Gobis, Katarzyna</creatorcontrib><creatorcontrib>Tarasiuk, Jolanta</creatorcontrib><creatorcontrib>Seksek, Olivier</creatorcontrib><creatorcontrib>Stefanska, Barbara</creatorcontrib><creatorcontrib>Borowski, Edward</creatorcontrib><creatorcontrib>Garnier-Suillerot, Arlette</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tkaczyk-Gobis, Katarzyna</au><au>Tarasiuk, Jolanta</au><au>Seksek, Olivier</au><au>Stefanska, Barbara</au><au>Borowski, Edward</au><au>Garnier-Suillerot, Arlette</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2001-02-16</date><risdate>2001</risdate><volume>413</volume><issue>2</issue><spage>131</spage><epage>141</epage><pages>131-141</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity of many natural cytotoxins. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the pump-mediated efflux. Here, we studied three members of a new family of benzoperimidine antitumor compounds which exhibit comparable cytotoxicity towards resistant cells expressing P-glycoprotein, or MRP1, and sensitive cells. We used spectrofluorometric methods to determine the kinetics of the uptake and release of these three drugs in different cell lines: the erythroleukemia cell line K562 and the resistant K562/Adr expressing P-glycoprotein, the small-cell lung cancer cell line GLC4 and resistant GLC4/Adr expressing MRP1. We also studied, using confocal microscopy, the intracellular distribution of these drugs in NIH/3T3 cells. Our data show that (i) the kinetics for the uptake of these drugs is very rapid, higher than 2×10 −17 mole cell −1 s −1, (ii) the drugs are strongly accumulated in the nucleus and lysosomes, (iii) the three drugs are recognized and pumped out by both transporters, as shown by the inhibition of P-glycoprotein- and MRP1-mediated efflux of pirarubicin by benzoperimidine, with inhibitory constants of 1.5 and 2.1 μM for P-glycoprotein and MRP1, respectively, suggesting that benzoperimidine is transported by the two transporters with K m∼2 μM. In conclusion, the fast uptake kinetics of the benzoperimidines counterbalance their efflux by P-glycoprotein and MRP1.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>11226386</pmid><doi>10.1016/S0014-2999(01)00728-2</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2001-02, Vol.413 (2), p.131-141
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_70651589
source MEDLINE; Elsevier ScienceDirect Journals
subjects 3T3 Cells - drug effects
3T3 Cells - metabolism
Animals
Antibiotics, Antineoplastic - pharmacology
Antineoplastic agents
Antineoplastic Agents - metabolism
Antineoplastic Agents - pharmacology
ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects
ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism
Benzoperimidine
Biological and medical sciences
Cell Nucleus - metabolism
Chemotherapy
DNA - metabolism
Doxorubicin - analogs & derivatives
Doxorubicin - pharmacology
Drug Resistance, Multiple - physiology
Drug Screening Assays, Antitumor - methods
Genes, MDR - drug effects
Genes, MDR - physiology
Humans
K562 Cells - drug effects
K562 Cells - metabolism
Lysosomes - metabolism
Medical sciences
Mice
MRP1 (multidrug resistance-associated protein)
Multidrug resistance
P-glycoprotein
Pharmacology. Drug treatments
Quinazolines - chemistry
Quinazolines - metabolism
title Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T10%3A22%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transport%20of%20new%20non-cross-resistant%20antitumor%20compounds%20of%20the%20benzoperimidine%20family%20in%20multidrug%20resistant%20cells&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Tkaczyk-Gobis,%20Katarzyna&rft.date=2001-02-16&rft.volume=413&rft.issue=2&rft.spage=131&rft.epage=141&rft.pages=131-141&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(01)00728-2&rft_dat=%3Cproquest_cross%3E70651589%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70651589&rft_id=info:pmid/11226386&rft_els_id=S0014299901007282&rfr_iscdi=true